Not Signed In -
Rectal Diseases |
|
|
Clinical Trial: A Study of Preoperative Radiation Therapy and Capecitabine in Locally Advanced Rectal Cancer.
This study is currently recruiting patients.
Purpose
To study of the efficacy of preoperative radiation therapy and capecitabine in locally advanced rectal cancer.
| Condition | Intervention | Phase |
|---|---|---|
| Rectal Cancer Transmural Rectal Wall Invasion Nodal Metastasis | Drug: Capecitabine Procedure: Pelvic radiation | Phase II |
MedlinePlus related topics: Colorectal Cancer
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: A Phase 2 Study of Preoperative Radiation Therapy and Capecitabine (an Oral Fluropyrimidine Carbamate) in Locally Advanced Rectal Cancer.
Further Study Details:
Primary Outcomes: safety; response
Expected Total Enrollment: 66
Expected Total Enrollment: 66
Study start: January 2002
To study of the efficacy of preoperative radiation therapy and capecitabine in locally advanced rectal cancer.
Eligibility
Ages Eligible for Study: 17 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- biopsy - proven rectal cancer, transmural rectal wall invasion, Karfnosky performance status >70, normal bone marrow, liver and kidney function
Exclusion Criteria:
- distant metastases, prior pelvic radiation, inflammatory bowel disease, severe ischemic heart disease, anticoagulant therapy, pregnancy
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00122291
Alexander Chan, MD 403-521-3013 alexc@cancerboard.ab.ca
Alfred Wong, MD
Alfred Wong, MD
Canada, Alberta
Tom Baker Cancer Centre, Calgary, Alberta, T2N 4N2, Canada; Recruiting
Rachel Syme, PhD
Study chairs or principal investigators
Alexander Chan, MD, Principal Investigator, Alberta Cancerboard
More Information
Study ID Numbers: Capcetabine Phase 2; 16080
Record last reviewed: July 2005
Last Updated: July 25, 2005
Record first received: July 21, 2005
ClinicalTrials.gov Identifier: NCT00122291
Health Authority: Canada: Health Canada
ClinicalTrials.gov processed this record on 2005-07-26
Record last reviewed: July 2005
Last Updated: July 25, 2005
Record first received: July 21, 2005
ClinicalTrials.gov Identifier: NCT00122291
Health Authority: Canada: Health Canada
ClinicalTrials.gov processed this record on 2005-07-26
email this page
print this page
bookmark this page
feedback on this page
